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Background. The World Health Organization recommends mass treatment as part of a trachoma control
strategy. However, scant empirical data from hyperendemic communities exist on the number of rounds of
treatment needed to reach a goal of ,5% prevalence in children. We determined the prevalence of trachoma and
infection with Chlamydia trachomatis in communities after 3–7 years of annual mass treatment in Tanzania.
Methods. Seventy-one communities with trachoma and annual azithromycin coverage data were enrolled.
A cross-sectional survey of R100 randomly selected children aged ,5 years in each community was performed.
Children were examined for clinical trachoma, and swab samples were taken for determination of ocular
C. trachomatis infection.
Results. After 3 years of mass treatment, the prevalence of trachoma decreased in a linear fashion with number of
years of mass treatment, whereas decreased prevalences of C. trachomatis infection were related to the extent of the
previous year’s azithromycin coverage. Our model suggests that, for communities with baseline trachoma
prevalence of 50% and annual treatment coverage of 75%, .7 years of annual mass treatment will be needed to
reach a prevalence of trachoma of ,5%.
Conclusions. Country programs in trachoma-endemic regions must realistically expect that several years of
annual mass treatment may be necessary to eliminate trachoma.
Trachoma, an eye disease caused by repeated and/or
prolonged episodes of Chlamydia trachomatis, is the
leading infectious cause of blindness worldwide [1]. In
recognition of this major public health problem,
the World Health Organization (WHO) has endorsed
the SAFE strategy for trachoma control: surgery (for late
complications), antibiotics (to reduce the pool of
infection in the community), face-washing, and envi-
ronmental improvements (to interrupt transmission).
The WHO has set an Ultimate Intervention Goal of
reducing the prevalence of follicular trachoma to ,5%
in children aged 1–9 years. Where follicular trachoma
prevalences are .10%, mass treatment of the commu-
nity is recommended. A donation program of azi-
thromycin has permitted wide-scale availability of
single-dose treatment for endemic communities, and
mass treatment has been shown to be effective for rapid
reduction of infection rates [2–4]. There are modest
data from countries where trachoma is not hyperen-
demic to suggest that 1–3 rounds of mass drug ad-
ministration are sufﬁcient to decrease the prevalence of
trachoma to ,5% [5–7]. However, reemergence after
programs consisting of 1 or 2 rounds of mass treatment
has been reported from countries with a starting prev-
alence that is high, which suggests that discontinuation
after insufﬁcient clearing is problematic [8, 9]. For these
settings, there are scant data to suggest the number of
rounds of annual mass treatment that are needed in
program settings to reduce trachoma and infection
prevalence to ,5%.
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on data from a single village in a hypoendemic area, where
a single round of mass treatment with azithromycin at 98%
coverage (plus provision of tetracycline ointment to all pa-
tients with clinical cases of infection at 6, 12, and 18 months)
reduced the infection rate to ,1% for up to 60 months and
reduced the prevalence of trachoma in children aged 1–9 years
from .20% to ,2.6% 5 years later [2, 10]. The perception of
the adequacy of a single round of mass treatment is un-
fortunate, as it has raised expectations for the short length of
commitment needed by drug donors, program funders, and
the countries themselves. Thus, data from many communities
in programs where starting prevalences are known and cov-
erage data are available are urgently needed to address the
question of how many rounds may be needed to decrease the
prevalence of trachoma to ,5%.
We conducted a cross-sectional study of sentinel children,
aged 6 months to 5 years, living in 71 communities that have
been the recipient of between 3 and 7 years of mass treatment
with azithromycin under a National Trachoma Control Pro-
gram in Tanzania. The purpose was to determine the effect of
the number of years of mass treatment on the prevalence of
C. trachomatis infection and clinical trachoma, and to model the
trajectory of decline and number of years needed to reach 5%
prevalence in these communities.
METHODS
Trachoma Control Program
The Tanzania National Trachoma Control Program started with
azithromycin in 1999, in 6 trachoma hyperendemic districts,
and in 6 communities in each district. The program was scaled
up during the ensuing years, adding districts and communities
within districts, to 54 districts at present, with all communities
in the districts slated for annual antibiotic distribution. The
number of years of mass treatment in the communities prior to
oursurveywasdeterminedpreciselyfrom antibioticdistribution
records showing the date that mass treatment began in a com-
munity and the date for each subsequent year. Logistic and
funding considerations dictated the process of scale-up, partic-
ularly in terms of adding districts. The program also had
a component of education on keeping children’s faces clean and
improving environmental sanitation that was national in scope,
with training for village health workers.
Baseline surveys for trachoma were carried out by the
program in sentinel communities, which were randomly
selected in the district prior to the start of the intervention.
The surveys were carried out using trained trachoma graders
who determined the presence of follicular trachoma and
intense trachoma in a random sample of children aged 1–5
years in each community. Infection was not assessed at
baseline.
Study Communities
To be eligible for this study, a community had to have a baseline
survey prior to the intervention conducted by the Kongwa
Trachoma Project Team, have received R3r o u n d so fm a s s
treatment, have data on estimated coverage of the community
with azithromycin for .50% of the annual rounds of
mass treatment, and consent to participate. Three rounds of
mass treatment were chosen as a minimum, because WHO
guidelines suggest that 3 rounds of mass treatment must be
provided and then the communities resurveyed for ongoing
need. All communities approached for the study agreed to
participate.
We stratiﬁed all eligible communities according to number of
roundsofmasstreatment.Inthestratumof3rounds,6ofthe 12
communities were not eligible, because they had inadequate
baseline surveys and likely had no trachoma [11]. In the stratum
of 4 rounds, all communities came from 1 district that was the
1 newdistrict enrolled thatyear,a districtknown tohavea lower
prevalence of trachoma than did the other districts at baseline.
In all other strata, communities from multiple districts were
included. In all, 71 communities were selected and studied.
Follow-up Surveys
Starting in 2007 in each village, our census team created a list of
all households in the village. We randomly selected sufﬁcient
households in each village to yield R100 households with
children in the age range 6 months to 5 years. A complete census
of all selected households was performed, and if there was .1
child within the age range, 1 was randomly selected to avoid
clustering of data by household. At the time of the census, the
interviewer asked whether the household had a latrine and
veriﬁed an afﬁrmative answer visually.
The children were examined by 1 experienced grader, using
2.5 loupes, who graded the conjunctiva of both eyes for the
presence of trachoma using the WHO Simpliﬁed grading
scheme [12]; follicular trachoma is deﬁned as the presence of
5o rm o r ef o l l i c l e so fs i z e.0.5 mm. Intense trachoma is deﬁned
as the presence of inﬂammation severe enough to obscure
.50% of the deep tarsal vessels. Trachoma is deﬁned as the
presence of follicular trachoma and/or intense trachoma. Pho-
tographs of the left upper eyelid were taken for every child,
and a sample of 50 photographs regraded at 3 time points to
ensure the absence of drift in grading over time. At the time
of the exam, the child’s face was also assessed for cleanliness,
using the presence or absence of 3 signs: nasal discharge, ocular
crusting, and/or ﬂies on the face when observed for 3 seconds
[13]. The absence of all 3 signs was considered to signify a
clean face.
Swab samples were taken of the upper conjunctiva of the left
eye, using standard procedures to avoid ﬁeld contamination,
and stored dry at 220C until shipped to the International
Chlamydia Laboratory at Johns Hopkins. A total of 213 ﬁeld
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none had positive results. At the laboratory, a C. trachomatis
qualitative polymerase chain reaction assay (Amplicor; Roche
Molecular Systems) was performed, according to the manu-
facturer’s directions, to identify samples with positive results.
Results were considered negative if the optical density was
,0.2 A450 and positive if R0.8 A450.
All procedures and protocols were reviewed and approved
by the Johns Hopkins institutional review board and the
National Institute for Medical Research of Tanzania. Parents
provided informed, written consent for participation of their
children.
Treatment Coverage
Azithromycin was provided as a single dose, 20 mg/kg up to 1 g.
Children aged ,1 year were treated with topical tetracycline,
twice per day for 4–6 weeks. Women who reported
being pregnant were also treated with topical tetracycline; no
pregnancy testing was performed.
Dataonannualmasstreatmentcoverageofcommunitieswith
azithromycin was obtained from 1999 through 2004 from the
International Trachoma Initiative ofﬁce in Tanzania. The data
were recorded as the number of persons treated and the es-
timated population in the community. In some cases, the
estimated population was the population resident in the com-
munity at the time of mass treatment and did not include those
who were temporarily absent. In 2005, the mass treatment
program devolved to the communities, and data on coverage
were collected from each community. In this case, the com-
munity health workers kept a treatment book in which in-
formation about individuals who were treated was recorded.
Antibiotic treatment was observed by health workers in each
community.Theyweregiven doses of azithromycinatthe outset
and 2 weeks to complete mass treatment before the remaining
antibiotic was returned to the district headquarters. At the time
of this study, there was no other source of azithromycin in the
communities. No payment was provided to health care workers
for this activity, and supervision was provided by the districts.
However, with these caveats, the national program did provide
sufﬁcientdoses onthe basis ofestimatedneedtoundertakemass
treatment in each community, which was as recorded.
The Tanzania program suspended mass drug administration
in 2006 in order to conduct impact surveys. We started our
surveys before resumption of mass drug administration, so
communities would have not been treated during a period of
1–2 years prior to our surveys.
Data Analyses
The rate of coverage with azithromycin was deﬁned as the
number of persons treated divided by the number of persons in
the community, according to community records. As indices
of coverage rate we examined percentage of annual coverage
.80%, .75%, average coverage of all mass treatments, and last
treatment coverage. Associations with each index were explored,
andthemostreasonableﬁt,intermsofsigniﬁcancelevel,wasthe
model using average treatment coverage.
An ordinary linear regression model was used to estimate
trachoma prevalence at follow-up as a function of baseline
prevalence, number of years of mass treatment, and a descriptor
of treatment coverage. Smoothed scatter plots (LOWESS func-
tion in S) were used to examine the assumption of a linear
relationship between trachoma and possible independent
predictors; the plots indicated that linear models were appro-
priate. For a model of prevalence of C. trachomatis infection,
a linear model was attempted, but after a number of
transformations were attempted, a linear model was never a
good ﬁt because of the number of communities with zero cases
of infection. Instead, we used a binary logistic regression model
to predict the odds of zero cases of infection. In addition, the
best index of coverage for infection was coverage at last treat-
ment round.
RESULTS
The average prevalence of trachoma in children aged %5y e a r s
prior to any mass treatment in these communities was 51%
(range, 19%–83%), and 1.6% of trachoma was intense trachoma
alone (Table 1) Reported coverage of the communities with
annual mass treatment varied widely (Table 1). Although
achieving 80% coverage was the program target, the overall
mean was 78% and estimates of the percentage of annual cov-
erage rates that exceeded even 75% varied from 41% to 75%.
At follow-up, the prevalence of trachoma varied from 20% in
communities with 3 prior rounds of mass treatment to 9% in
communities with 7prior rounds of annual masstreatment(Table
2). The prevalence of infection averaged 8% in those communities
with 3 rounds of mass treatment, compared with 6% in those with
7 rounds of annual mass treatment. The decline in the prevalence
of infection was not linear and seemed to stabilize after 5 rounds.
The average proportion of children with clean faces was lowest in
the communities with 3 rounds of treatment and highest in the
communities with 7 rounds of treatment. The communities with
3 rounds of treatment also had the lowest proportion of house-
holds with latrines, with no clear trend by rounds of treatment.
B e c a u s eb a s e l i n er a t e so ft r a c h o m aa r eap r e d i c t o ro fs u b s e q u e n t
rates,we constructed a model predicting trachoma prevalences that
controlled for preprogram rates. A multivariate linear model of
trachoma prevalence, adjusted for baseline trachoma rate and the
average treatment coverage, sugg e s t e dt h a te a c ha d d i t i o n a lr o u n d
of mass treatment beyond 3 years decreased the prevalence by an
absolute value of 1.6% (Table 3). According to our model, the
most dramatic decrease in the prevalence of trachoma occurred
during the ﬁrst 3 rounds of treatment, as shown by the intercept,
from a 50% prevalence before mass treatment to an estimated
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with average coverage of 75% and a starting trachoma prevalence
of 50%, it will take .7 rounds and likely closer to 10 rounds of
annual mass treatment to reach a prevalence of trachoma ,5%.
There was no additional beneﬁt seen when adding to the model
variables on clean faces or latrines.
Creating an appropriate model for infection was not
straightforward, because of the number of communities with no
cases of infection and the absence of infection data at baseline to
use for adjustment. In a logistic model predicting absence of
infection, only baseline level of trachoma was a signiﬁcant pre-
dictor. No measure of coverage or number of rounds of mass
treatment was statistically signiﬁcantly related to absence of
infection. The best metric for coverage was using the estimate of
coverageonthelastroundofmasstreatment;anincreaseof10%
in coverage with the last round was associated with a 41% in-
crease in the odds of zero cases of infection in a community but
was not statistically signiﬁcant (P 5 .22) (Table 4). The model
suggested that at a baseline trachoma prevalence of 50%, after
R3 rounds of mass treatment, and the last round with coverage
of 75%, the probability of having zero infection in a community
was only 0.10 (95% conﬁdence interval, 0.04–0.24).
DISCUSSION
The results of this study suggest that, in a realistic country pro-
gram setting, it will take longer than 7 years and may take as long
as 10 years of annual mass treatment in communities where
baseline prevalence is .50% and treatment was stopped for
1yeartoreducetheprevalenceoftrachomato5%.Findingsfrom
studies evaluating 1 or more rounds of mass treatment in
hyperendemic settings support this ﬁnding. In a hyperendemic
community in a high-prevalence district in Tanzania, a single
round of mass treatment with overall coverage of 89% reduced
infection rates but did not eliminate infection, and there was
evidence for reemergence at 12 months [8]. After 2 rounds of
masstreatment,asurveyat5yearsrevealedtrachomaprevalences
that were still .30% [14]. In hyperendemic communities in
Ethiopia, after 4 rounds of biannual mass treatment, with high
coverage, the prevalence of infection decreased to 2.6%, but once
treatment stopped, the prevalence of infection returned to 25%
by 18 months [9]. In data from Mali, the national program had
seemingly reduced the prevalence of trachoma to ,5% from
17% in the highest prevalence area after 3 rounds of mass
treatment, but 3 yearslater trachoma had startedto reemerge [6].
Our data clearly suggest that baseline prevalence of trachoma
is an important predictor of current trachoma and infection
rates in a community. For every 10% increase in the baseline
prevalence of trachoma, the ending prevalence of trachoma after
3 years was higher by an absolute value of 2%, independent of
number of rounds of treatment or coverage. The ﬁnding that
subsequent infection or trachoma is predicted by previous tra-
choma/infection status has been reported by us and others
previously [9, 15, 16] and remains a critical observation: The
Table 1. Prevalence of Trachoma in Preschool-Age Children in 71 Communities Prior to Start of Mass Treatment With Azithromycin, and
Estimates of Annual Azithromycin Treatment Coverage, by Number of Years of Mass Treatment Rounds













3 6 59.9 (48.9–77.7) 71.3 (57.0–86.3) 41.7
4 17 40.7 (18.9–74.0) 79.4 (56.1–97.6) 75.0
5 15 49.6 (24.8–74.6) 81.1 (58.9–94.0) 71.7
6 16 58.9 (34.1–83.3) 76.9 (59.0–84.7) 62.8
7 17 53.0 (23.2–80.4) 78.2 (65.1–85.4) 67.2
Total 71 51.2 (18.9–83.3) 78.2 (56.1–97.6) 66.9
Table 2. Average Prevalence of Trachoma and Chlamydia trachomatis Infection, and Measures of Clean Faces and Latrines in











mean % (95% CI)
Prevalence of infection,
mean % (95% CI)
3 37.5 (24.6–50.3) 9.7 (0.3–19.0) 20.3 (7.9–32.8) 7.8 (0.8–14.8)
4 50.6 (45.2–55.9) 59.1 (43.8–74.4) 9.3 (5.1–13.5) 2.8 (1.3–4.3)
5 45.1 (40.2–50.0) 69.6 (56.7–82.5) 12.8 (8.2–17.5) 6.4 (2.2–10.6)
6 46.1 (40.6–51.6) 62.9 (53.4–72.5) 12.6 (8.9–16.2) 5.8 (2.8–8.7)
7 51.6 (45.9–57.6) 67.9 (59.0–76.7) 9.1 (6.4–11.7) 6.1 (4.1–8.2)
NOTE. Trachoma refers to active disease (follicular trachoma or intense trachoma). CI, conﬁdence interval.
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the prevalence after 3 or more rounds of mass treatment, so
program managers should not expect the same results for the
same coverage in communities where the starting prevalence is
20%as in those where the starting prevalence is 50%. These data
suggest that the WHO guideline to resurvey after 3 rounds of
annual mass treatment might be reﬁned on the basis of starting
prevalence and whether there was any interruption in annual
mass treatment, as there is no value in using resources for sur-
veys to determine whether 5% prevalence has been achieved
after 3 years of mass treatment in hyperendemic areas.
Although the number of rounds of mass treatment was sig-
niﬁcantly related to lower prevalence of trachoma, the coverage
rate was not related. We showed data for average treatment
coverage, but even using the percentage of coverage rates .75%
and .80%, the coverage indicator was not signiﬁcantly related
to trachoma prevalence. The lack of association may in part be
attributed to the imprecision of the program data on coverage.
The trachoma control program in Tanzania was under pressure
to achieve high coverage rates, which may have affected
reporting by the districts. Thus, coverage may be overestimated
in this study. Also, in some cases individuals who missed mass
treatment in one village may have traveled to another nearby
village for treatment, thus skewing the data for both villages.
Finally, the effect in all villages of a ‘‘national treatment holiday’’
may have muted the effect of coverage. Because of these un-
certainties, our data should not be interpreted to mean that
coverage levels were not important.
These ﬁndings should also be interpreted against the back-
drop of the Tanzania National Trachoma Control Program’s
attempts to implement a hygiene improvement campaign. We
did not collect data on the implementation of their program to
improve face washing and sanitation, but some of the declrease
(or lack thereof) may be due to variations in the success of this
program component. At follow-up, we did not observe a linear
increase inproportion of householdswithlatrinesor proportion
of children whose faces were clean by stratum.
Our model for infection also supported the ﬁnding that
multiple rounds of mass treatment, beyond 3, would be needed
to increase the likelihood that infection would be eliminated.
However, after 3 rounds of mass treatment we did not ﬁnd any
metric related to coverage, or number of rounds of mass treat-
ment, to be signiﬁcantly related to infection. The best metric, in
terms of approaching the closest to signiﬁcance, was percent
coverage at the last round of mass treatment. In longitudinal
studies, infection rates decrease dramatically after treatment
and, even if there is reemergence, take time to return [8, 9, 17].
Thus, it makes sense that the infection rates that we observed
cross-sectionally may be sensitive to the last round of mass
treatment; it is possible that a particularly high coverage rate in
the immediate past year, or low coverage, would have negated
somewhat the effects of previous rounds in the community. In
addition, the imprecision of adjustment by baseline trachoma
prevalence, rather than infection prevalence, may have affected
ourabilitytodetectdifferences.Ideally,infectiondataatbaseline
would have informed these analyses, but they were not collected
by the program. Although there is reasonable correlation be-
tween cases of infection and the presence of trachoma, and our
infection model supports an association, baseline infection data
would have likely enabled better predictions. In the stratum of 4
roundsofmasstreatment,forexample,where baseline trachoma
prevalences were lowest, almost one-quarter of communities
had nocasesof infectionatfollow-up. Ifthecommunities in this
district had already had low infection rates at the outset,
this high rate of clearance would be more understandable. As it
is, with only the ability to adjust for baseline trachoma preva-
lence,the relationshipofnumberofrounds ofmasstreatmentto
prevalence of infection is likely somewhat blunted. The effect of
the treatment holiday in potentially allowing reemergence is also
likely to have affected the infection rate that we observed and to
have blunted the effect of multiple rounds of mass treatment.
Nevertheless, the absence of a clear decline after multiple rounds
Table 3. Multivariable Linear Model Predicting Trachoma
According to Number of Years (Past 3) of Annual Mass Treatment
With Azithromycin
Characteristic b (95% CI), % P
Intercept





No. of rounds of
mass treatment
(per round)




20.8 (22.8 to 1.1) .41
NOTE. CI, conﬁdence interval.
a Centered at 50% prevalence at baseline, 3 rounds of treatment, and
average treatment coverage with azithromycin of 75%.
Table 4. Multivariable Logistic Model Predicting Odds of Zero
Cases of Infection With Chlamydia trachomatis in Communities
Characteristic b (95% CI), % P
Intercept








0.35 (20.21 to 0.90) .22
NOTE. CI, conﬁdence interval.
a Centered at 50% baseline prevalence of trachoma and last treatment
coverage with azithromycin of 75%. The probability of no infection after at least
3 rounds of treatment in a community with 50% baseline prevalence of active
trachoma and last treatment coverage of 75% is equal to e
22.13/(11e
22.13)5 0.10.
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higher coverage than the program is currently able to achieve
may be needed to have an effect.
The sample of 71 communities, with data from up to 7
y e a r so fm a s st r e a t m e n t ,i sas t r e n g t ho fo u rs t u d y .O t h e r
s t u d i e sh a v eu s e ds i n g l ev i l l a g e so rm u c hs h o r t e rp e r i o d so f
time to report on the disappearance or reemergence of trachoma
and to make projections [4, 8, 10, 18, 19]. For example, a recent
paper suggesting that 2 rounds of treatment would be enough
for trachoma control in Tanzania was based on a sample of
15 neighborhoods all in the same village [20]. Our data, based
on random samples from 71 communities scattered all over
Tanzania, suggest that a far greater commitment of time will be
needed in a programmatic context to achieve trachoma control.
Because trachoma control program managers only have clinical
trachoma rates to guide program success, these data are more
relevant than the data on C. trachomatis infection, at least until
a ﬁeld-usable, rapid test is available.
In summary, data from this cross-sectional survey of children
in 71 communities where the average starting prevalence was
.50% and a ‘‘treatment holiday’’ occurred suggest that, after 3
rounds of mass treatment, no communities had a prevalence
that would warrant stopping mass treatment under program
conditions. With each additional round of treatment, the
prevalence of trachoma declined, but .7 rounds (we estimated
10rounds ofmasstreatment) willbeneededtoreach5%ratesof
trachoma in such a setting. The effect of improving coverage of
mass treatment, ceasing interruptions of treatment, and the
added beneﬁt of improvement in socioeconomic conditions
mayenhancereduction intrachomaandshortenthe timeframe,
but this supposition warrants additional research.
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